Steven Cohen Fibrogen Inc Transaction History

Point72 Asset Management, L.P.

$39.3 Billion
Q1 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Fibrogen Inc stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 1,080,264 shares of FGEN stock, worth $777,790. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,080,264

Previous 1,600,000 32.48%

Holding current value

$777,790

Previous $1.42 Million 78.23%

% of portfolio

0.01%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.73 - $2.73 $788,592 - $2.95 Million	1,080,264 New	1,080,264 $2.54 Million
Q3 2023 Nov 14, 2023	BUY	$0.79 - $2.83 $10,412 - $37,302	13,181 New	13,181 $11,000
Q1 2023 May 15, 2023	SELL	$15.95 - $25.18 $21.6 Million - $34.1 Million	-1,355,218 Reduced 28.34%	3,426,427 $63.9 Million
Q4 2022 Feb 14, 2023	BUY	$13.27 - $17.73 $52,350 - $69,944	3,945 Added 0.08%	4,781,645 $76.6 Million
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $3.29 Million - $4.21 Million	-288,592 Reduced 5.7%	4,777,700 $62.2 Million

Q2 2022 Aug 15, 2022	SELL	$7.94 - $12.96 $6.08 Million - $9.93 Million	-765,869 Reduced 13.13%	5,066,292 $53.5 Million
Q1 2022 May 16, 2022	BUY	$12.02 - $16.79 $25.2 Million - $35.3 Million	2,099,567 Added 56.25%	5,832,161 $70.1 Million
Q4 2021 Feb 14, 2022	BUY	$9.93 - $15.39 $26 Million - $40.3 Million	2,621,494 Added 235.94%	3,732,594 $52.6 Million
Q3 2021 Nov 15, 2021	BUY	$10.18 - $26.64 $11.3 Million - $29.6 Million	1,111,100 New	1,111,100 $11.4 Million

Others Institutions Holding FGEN

# of Institutions

120

Shares Held

62.2M

Call Options Held

1.54M

Put Options Held

221K

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $67.5M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account